BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, ...

Another recent federal study, published in the journal JAMA Pediatrics in February, showed approximately 1.01 million ...

Five years ago on Tuesday, the World Health Organization declared COVID-19 a global pandemic, and the impact of the virus and ...

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Novavax (NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue expectations. The company ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

The current COVID-19 vaccine is 33% effective at preventing emergency department or urgent care visits among adults of all ages. It also is 45% to 46% effective at preventing hospitalizations in older ...

The Iowa Senate bill alters a proposal that would have penalized administering gene-based vaccines including the COVID-19 ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker.